Thyrocare’s strategy shift drives steady turnaround

THYROCARE TECHNOLOGIES' STEADY revival is beginning to bear fruit, as the strategic course it charted two years ago continues to translate into stronger growth and healthier margins. The diagnostics firm’s July-September quarter performance underlines that shift, powered by operational efficiency, a sharper franchise model,and disciplined cost control, markingaclearturnaround from its post-Covid slump.

- AYANTI BERA

After a turbulent period following its 2021 acquisition by API Holdings, parent of PharmEasy, Thyrocare undertook a broad restructuring in FY24 aimed at stabilising its core business. It streamlined costs, introduceda“pay-for-performance” — compensation model across its franchise network, and recalibrated its focus towards sustainable, volume-led growth. Those measures are nowyielding visible results.